Re: Warrant Holder Meeting

ReNeuron Group plc
21 September 2006



                       Results of Warrant Holder Meeting



Guildford, UK, 21 September 2006: ReNeuron Group plc (LSE: RENE) today announces
that all resolutions put to Warrant holders at a meeting of Warrant holders held
on 21 September 2006 (the Meeting) were passed.



In accordance with the resolutions passed at the Meeting the terms of the
Instrument constituting the Warrants has been amended such that:



•          the price payable on exercise of the Warrants has been reduced from
30p per Ordinary Share to 10p per Ordinary Share; and



•          the period within which the Warrants may be exercised has been
shortened such that the last date on which Warrants may be exercised has been
brought forward from 12 February 2007 to 12 December 2006.



The Directors believe that such amendments are in the best interests of the
Company and that the shortening of the exercise period and the reduction in the
subscription price will provide a greater opportunity for the Warrants to be
exercised thereby providing the Company with a potential source of further
finance in the immediate future.



Enquiries:



ReNeuron
Michael Hunt, CEO                                       Tel: [phone]
John Sinden, CSO



Financial Dynamics
David Yates                                             Tel: [phone]
Sarah Macleod





Notes to Editors



ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.



ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.



The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  Subject to successful completion of pre-clinical
testing, the Company plans to file for approval to commence a Phase I clinical
study in stroke by the end of 2006, with the study commencing as soon as
possible thereafter.



The Group has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a rare, genetic and fatal
neurodegenerative disorder that affects around 1 in 10,000 people.  This
programme is in pre-clinical development.



In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange